Skip to content

A comparative study To determine The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) In Patients Undergoing Hair Transplantation

A Prospective, Multicentric, Open Label, Randomized, Bio-Interventional, Phase I/II Pilot Study To Evaluate The Safety And Efficacy Of Autologous Human Platelet Lysate (HPL) For Treatment Of Androgenetic Alopecia (AGA) In Patients Undergoing Hair Transplantation

Status
Active, not recruiting
Phases
Phase 1Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/04/002613
Enrollment
30
Registered
2012-04-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Androgenetic Alopecia

Interventions

Intervention1: Autologous Human Platelet Lysate (HPL): Hair follicles dipped in HPL before transplant Intervention2: Autologous Human Platelet Lysate (HPL): Hair follicles dipped in HPL before transpl
followed by one HPL injection after transplant Intervention3: Autologous Human Platelet Lysate (HPL): Hair follicles dipped in HPL before transplant followed by one HPL injection (5 ml)at an interval

Sponsors

Kasiak Research Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male subjects, aged between 18 to 50 years (both inclusive) and in general good health 2. Subjects willing to refrain from other AGA treatments during the entire study duration 3. Subjects who are willing to give informed consent and adhere to the study protocol

Exclusion criteria

Exclusion criteria: 1. Subjects aged 50 years 2. Subjects with dermatological disorder of scalp that might interfere with study evaluation 3. Subjects on Anti-coagulant therapy 4. Subjects with clinically significant medical or psychiatric disease as determined by the investigator. 5. Subjects unwilling to or unable to comply with the study protocol. 6. Subjects taking concomitant therapy that might interfere with the study results in investigators opinion or participating in another trial in the past 30 days.

Design outcomes

Primary

MeasureTime frame
1. Increase in Hair Follicle viability after transplant 2. Improvement in Calibre & Density of Hair as assessed by Folliscope 3. Photographic assessment from randomization to end of study Timepoint: End Of Study - 4 Months

Secondary

MeasureTime frame
1. Physicianâ??s assessment score 2. Patients self assessment score Timepoint: End Of Study - 4 Months

Countries

India

Contacts

Public ContactDr Kaushal Shah

Hair Revive

drsattur@yahoo.com022-26136575

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026